Published in Invest New Drugs on June 08, 2011
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science (1999) 12.52
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature (2004) 6.77
Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature (1999) 5.38
A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A (1992) 4.61
Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer (2007) 4.16
p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J (1991) 3.55
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
Structural basis for the regulation of tubulin by vinblastine. Nature (2005) 3.10
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol (2006) 3.06
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res (2004) 1.91
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol (2003) 1.90
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol (1999) 1.87
Cell-cycle targeted therapies. Lancet Oncol (2004) 1.55
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol (2003) 1.51
VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle (2007) 1.41
Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res (2002) 1.34
Eg5 steps it up! Cell Div (2006) 1.18
Mitotic kinesins: prospects for antimitotic drug discovery. Curr Top Med Chem (2005) 1.14
HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res (2003) 1.12
Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem (2005) 1.11
Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res (2002) 1.10
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs (2007) 1.08
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs (2007) 1.04
Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry (1999) 1.01
Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs (2005) 0.97
Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Mol Cancer Ther (2009) 0.95
Novel agents that target tublin and related elements. Semin Oncol (2006) 0.95
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents. Curr Oncol Rep (2004) 0.92
Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J Nat Prod (2003) 0.89
Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. Am J Hematol (2008) 0.86
Therapeutic opportunities to control tumor cell cycles. Clin Transl Oncol (2006) 0.82
Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry (2005) 0.81
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs (2005) 0.80
Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy. Invest New Drugs (2008) 0.80
Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin. Biochemistry (2005) 0.78
JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem (2005) 2.76
Lipidic pore formation by the concerted action of proapoptotic BAX and tBID. J Biol Chem (2004) 2.06
Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem J (2002) 1.79
FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol (2011) 1.70
Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage (2004) 1.67
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
Tankyrases as drug targets. FEBS J (2013) 1.55
Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. J Biol Chem (2002) 1.54
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases. N Z Med J (2003) 1.47
Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab (2013) 1.42
Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem (2003) 1.35
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet (2004) 1.29
Tankyrase recruitment to the lateral membrane in polarized epithelial cells: regulation by cell-cell contact and protein poly(ADP-ribosyl)ation. Biochem J (2006) 1.27
Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res (2003) 1.26
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem J (2007) 1.21
Hypermetabolism, hyperphagia, and reduced adiposity in tankyrase-deficient mice. Diabetes (2009) 1.18
Physical exercise and quality of life in breast cancer survivors. Int J Med Sci (2008) 1.14
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol (2005) 1.13
Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem (2005) 1.10
Mitochondrial ceramide increases in UV-irradiated HeLa cells and is mainly derived from hydrolysis of sphingomyelin. Oncogene (2004) 1.09
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys (2002) 1.08
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest (2014) 1.06
Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol (2005) 1.06
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res (2006) 1.06
The use of bevacizumab in non-small cell lung cancer: an update. Anticancer Res (2014) 1.06
Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol (2013) 1.03
Phospholipid scramblase 3 is the mitochondrial target of protein kinase C delta-induced apoptosis. Cancer Res (2003) 0.99
Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab. J Thorac Oncol (2012) 0.98
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem (2007) 0.97
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett (2008) 0.97
Novel combretastatin analogues endowed with antitumor activity. J Med Chem (2006) 0.97
Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry (2008) 0.96
Mitochondrial kinases and their molecular interaction with cardiolipin. Biochim Biophys Acta (2009) 0.96
Phospholipid scramblase-3 regulates cardiolipin de novo biosynthesis and its resynthesis in growing HeLa cells. Biochem J (2007) 0.96
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol (2013) 0.95
Dermoscopic patterns of cutaneous melanoma metastases. Melanoma Res (2004) 0.93
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res (2006) 0.93
The Supportive Care Task Force at the University of L'Aquila: 2-years experience. Support Care Cancer (2005) 0.92
Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer (2012) 0.92
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clin Colorectal Cancer (2011) 0.91
The medical oncologist's role in palliative care: AIOM's position. Tumori (2010) 0.91
Activation of dual apoptotic pathways in human melanocytes and protection by survivin. J Invest Dermatol (2006) 0.91
Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity. J Med Chem (2008) 0.91
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res (2013) 0.91
Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem (2012) 0.90
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem (2008) 0.90
Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol (2013) 0.90
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer (2010) 0.90
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res (2014) 0.89
The interaction between tBid and cardiolipin or monolysocardiolipin. Biochem Biophys Res Commun (2005) 0.89
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. Breast Cancer Res Treat (2014) 0.88
Intradermal lymphoscintigraphy at rest and after exercise: a new technique for the functional assessment of the lymphatic system in patients with lymphoedema. Nucl Med Commun (2010) 0.87
Premetastatic niche: ready for new therapeutic interventions? Expert Opin Ther Targets (2012) 0.87
Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett (2007) 0.87
Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leuk Lymphoma (2011) 0.86
Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. Am J Hematol (2008) 0.86
Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. PLoS One (2012) 0.86
The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis. Int J Mol Med (2007) 0.86
Tankyrase-1 overexpression reduces genotoxin-induced cell death by inhibiting PARP1. Mol Cell Biochem (2005) 0.86
Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patients. Cancer Immunol Immunother (2007) 0.86
Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett (2006) 0.85
Adiponectin reduces thermogenesis by inhibiting brown adipose tissue activation in mice. Diabetologia (2014) 0.85
ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood (2003) 0.85
A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit (2009) 0.85
Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ (2009) 0.85
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.85
Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents Med Chem (2009) 0.84
A systematic review of experimental and clinical acupuncture in chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med (2013) 0.84
Tumors of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol (2012) 0.84
Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. Eur J Hum Genet (2006) 0.84
Predictors of existential and religious well-being among cancer patients. Support Care Cancer (2010) 0.84
Neurexin-1α contributes to insulin-containing secretory granule docking. J Biol Chem (2012) 0.83
Design, synthesis and biological evaluation of novel stilbene-based antitumor agents. Bioorg Med Chem (2008) 0.83
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem (2006) 0.82
Treatment-related side effects and quality of life in cancer patients. Support Care Cancer (2012) 0.82
Acupuncture in the treatment of menopause-related symptoms in women taking tamoxifen. Tumori (2002) 0.82
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast Cancer Res Treat (2003) 0.82